Angelalign Technology
Chinese maker of clear dental aligners using AI-driven treatment planning software, iOrtho.
On the record
Checkpoint: US ITC ruling on Align's import-exclusion complaint against Angelalign
The call
Angelalign is growing fast at home and abroad, but its international expansion sits inside an active patent fight with Align Technology whose outcome is still unresolved.
Angelalign makes invisible braces and the software that designs them, similar to Invisalign. The company is very profitable and growing quickly in China because Invisalign faces trade barriers there, but Invisalign's parent company is suing Angelalign in Europe and the U.S., claiming patent violations. A European court already forced Angelalign to remove features from its software, and the U.S. case could stop the company from selling there entirely. The one thing that matters most: whether Angelalign wins or settles the U.S. lawsuit, because losing could trap the company in China alone while Invisalign's parent company considers pushing into China or cutting prices worldwide.
Why
01
AI pressure: OrthoAI v2 (open-source AI treatment-planning tool). Open-source AI could replicate Angelalign's proprietary treatment-planning software, cutting into its data edge over time. Could AI do the core job? Only partly.
02
Bigger players: Align Technology, Inc. (Invisalign). Align's UPC injunction already forced Angelalign to pull a feature in Europe; a US ITC import-ban case is pending. Could a giant copy it? Probably.
03
What protects it. Home-market distribution, 2 million-case proprietary dataset, and Align's weaker footing in China protect its base business.
What would change this call
U.S. ITC ruling on Align's Sept 2025 import exclusion complaint against Angelalign. Would show whether Angelalign can legally sell in the U.S. market at all.
Further UPC or EPO rulings on Align's European patent disputes with Angelalign. Would show whether Angelalign keeps or loses core iOrtho features in Europe.
Angelalign's mainland China revenue growth versus case volume growth over next two quarters. Would show whether pricing pressure is eroding its home-market profit anchor.
Further UPC or EPO rulings on Align's European patent disputes with Angelalign. Would show whether Angelalign keeps or loses core iOrtho features in Europe.
Angelalign's mainland China revenue growth versus case volume growth over next two quarters. Would show whether pricing pressure is eroding its home-market profit anchor.
Key numbers
- FY2025 revenue $370.3 million, up 37.8%
- Ex-mainland revenue grew 102.5% in FY2025
- China mainland revenue up only 10.1% on 26.3% volume growth
Named risks
- ITC exclusion order could block Angelalign clear aligner imports into the U.S.
- Further UPC or EPO patent rulings could force removal of more iOrtho features in Europe.
- China mainland revenue growth (10.1%) trailing volume growth (26.3%) signals margin compression.
- Align Technology's activist-driven strategic review could yield aggressive pricing or China push.
- Rapid international manufacturing expansion (U.S., Brazil, planned Wisconsin) carries execution risk.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Align Technology | contesting | UPC injunction upheld July 2026 forced feature withdrawal; ITC complaint filed Sept 23, 2025 seeks U.S. import ban |
| Align Technology | losing to | Align's Q2 2026 clear-aligner revenue (~$856M) dwarfs Angelalign's full FY2025 revenue ($370.3M) |
| OrthoAI (open-source project) | gaining on | March 2026 release explicitly replicates commercial treatment-planning software, commoditizing that layer |
| SmileDirectClub | contesting | Named among top-5 clear aligner competitors in direct-to-consumer segment |
| Envista/Ormco (Spark) | contesting | Competing incumbent dental-device maker in the same clear aligner category |
Questions people ask
- Is Angelalign in financial trouble?
- No, the financials look strong as of the FY2025 report (2025-12-31): revenue reached USD 370.3 million, up 37.8% year over year, and adjusted net profit was USD 43.8 million, up 63.0%. Case volume also rose 48.1% to 532,400, so the pressure on Angelalign is legal and competitive, not a cash or profitability problem.
- Who are Angelalign's biggest competitors?
- Its main rival is Align Technology, maker of Invisalign, which is the dominant global player in clear aligners. Rather than competing mainly for customers, Align is contesting Angelalign directly through patent litigation at the US ITC, in US federal courts, and in Europe, aiming to block market access instead of winning business away with a better product.
- Is Angelalign at risk from AI?
- AI does not appear to be a threat to Angelalign right now. AI shows up inside Angelalign's own product as treatment-planning software rather than as an outside technology disrupting its business. The real pressure the company faces is patent litigation with Align Technology, not competition from AI-driven rivals.
- What is Angelalign's biggest risk right now?
- The biggest risk is patent litigation with Align Technology over its overseas expansion. Results have been mixed: the UPC Dusseldorf court dismissed a preliminary injunction request from Align on 2026-05-28, but the UPC Court of Appeal upheld an injunction against Angelalign's 'Live Now' feature on 2026-07-09. A further US ITC ruling on Align's import-exclusion complaint, filed 2025-09-23, is expected around January 2027 and is worth tracking.
- Is Angelalign actually growing outside China?
- Yes, and quickly. Ex-China revenue grew 102.5% year over year to USD 163.0 million on 256,200 cases (up 82.1%) in FY2025 (as of 2025-12-31), far outpacing mainland China revenue growth of 10.1% to USD 207.3 million. Whether this overseas growth rate keeps outpacing the China business through the FY2026 results, expected around March 2027, is a key thing to watch.
- How does Angelalign's product and business model score compare to peers?
- Angelalign's underlying product and business model look comparatively strong based on its results. FY2025 revenue rose 37.8% year over year to USD 370.3 million and adjusted net profit climbed 63.0% to USD 43.8 million (as of 2025-12-31), while case volume grew 48.1% to 532,400. It has also notched at least one legal win against Align Technology, with the UPC Dusseldorf court dismissing Align's request for a preliminary injunction on 2026-05-28, even as its legal footing elsewhere remains contested.
Timeline
- 2026-07-29Align Technology announces $400-500M buyback and board refresh after Elliott Management engagement
- 2026-07-15UPC Court of Appeal upholds injunction against Angelalign's 'Live Now' feature
- 2026-05UPC Dusseldorf rejects Align's infringement claim over A7 Premolar Extraction patent
- 2026-04-23Angelalign files FY2025 annual report showing 4,312 employees
- 2026-03-27Angelalign releases FY2025 results: $370.3M revenue, $43.8M adjusted net profit
- 2026-03-20Open-source OrthoAI v2 published, replicating commercial aligner treatment-planning pipelines
- 2026-02UPC Dusseldorf grants Align preliminary injunction over Angelalign's automated planning software
- 2025-09-23Align Technology files ITC complaint seeking to block Angelalign imports into the U.S.
- 2025-05Angelalign launches 'Live Now' automated treatment-plan feature in iOrtho Release 5.2
Revision history
30 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Passion for Clinical Excellence Drives Worldwide Growth (2026-03-27)
- Annual Report 2025
- gurufocus.com (2026-07-30)
- Align Technology adds directors, boosts buyback after Elliott talks (2026-07-29)
- Align and Carpmaels & Ransford defend PI in dental aligner technology (2026-07-15)
- Angelalign Applauds European Court Rejection
- Align Technology Files ITC Complaint (2025-09-23)
- Is automatic cephalometric software using AI better than orthodontist experts? (2023-07-07)
- OrthoAI v2 (2026-03-20)